Healey ALS Platform Trial - Regimen F ABBV-CLS-7262

Brief description of study

ABBV-CLS-7262 is a prodrug that is converted in vivo to the pharmacologically active parent compound A-1684909. A-1684909 is a central nervous system (CNS)-penetrant, eukaryotic translation initiation factor 2B (eIF2B) activator that attenuates the integrated stress response (ISR), a highly conserved cellular mechanism hypothesized to be important in the pathophysiology of amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions when activated chronically (Costa-Mattioli et al. 2020).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Amyotrophic Lateral Sclerosis,ALS
Age: Between 18 Years - 100 Years
Gender: All

Confirmed ALS diagnosis; greater than 50% FVC or SVC; less than 36 months since symptom onset; must either be not taking, or on a stable dose of Riluzole, Edaravone (Radicava), or Relyvrio

Updated on 09 Mar 2024. Study ID: 842770F

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).